Garfield Alastair 4
4 · RHYTHM PHARMACEUTICALS, INC. · Filed Jul 3, 2025
Insider Transaction Report
Form 4
Garfield Alastair
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-07-01+4,445→ 4,445 total - Sale
Common Stock
2025-07-02$64.81/sh−1,313$85,096→ 3,132 total - Exercise/Conversion
Restricted Stock Units
2025-07-01−4,445→ 13,333 total→ Common Stock (4,445 underlying) - Sale
Common Stock
2025-07-02$64.60/sh−6$388→ 3,126 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
- [F3]The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.